Isoray Stock Forecast, Price & News

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Isoray in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Isoray stock.
View analyst ratings for Isoray or view top-rated stocks.

1 Wall Street research analysts have issued 1-year price targets for Isoray's shares. Their ISR stock forecasts range from $1.25 to $1.25. On average, they anticipate Isoray's stock price to reach $1.25 in the next year. This suggests a possible upside of 349.6% from the stock's current price.
View analysts' price targets for Isoray or view top-rated stocks among Wall Street analysts.

Isoray's stock was trading at $0.38 at the beginning of 2022. Since then, ISR stock has decreased by 26.8% and is now trading at $0.2780.
View the best growth stocks for 2022 here.

Isoray is scheduled to release its next quarterly earnings announcement on Monday, September 19th 2022.
View our earnings forecast for Isoray.

Isoray, Inc. (NYSEAMERICAN:ISR) posted its quarterly earnings data on Tuesday, May, 10th. The healthcare company reported ($0.01) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.01). The healthcare company had revenue of $2.91 million for the quarter, compared to analysts' expectations of $3.15 million. Isoray had a negative net margin of 48.05% and a negative trailing twelve-month return on equity of 9.19%.
View Isoray's earnings history.

Some companies that are related to Isoray include Tactile Systems Technology (TCMD), Apollo Endosurgery (APEN), Quipt Home Medical (QIPT), Profound Medical (PROF), Sensus Healthcare (SRTS), NeuroPace (NPCE), AVITA Medical (RCEL), Retractable Technologies (RVP), Retractable Technologies (RVP), Meihua International Medical Technologies (MHUA), Invo Bioscience (IVOB), CVRx (CVRX), DarioHealth (DRIO), LMF Acquisition Opportunities (LMAO) and Repro Med Systems (KRMD).
View all of ISR's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Isoray investors own include Brainstorm Cell Therapeutics (BCLI), OPKO Health (OPK), Bausch Health Companies (BHC), Anavex Life Sciences (AVXL), TherapeuticsMD (TXMD), Catalyst Pharmaceuticals (CPRX), MannKind (MNKD), CTI BioPharma (CTIC), Idera Pharmaceuticals (IDRA) and Palatin Technologies (PTN).

Isoray trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "ISR."

Isoray's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Bard Associates Inc. (0.47%), State Street Corp (0.39%), Taylor & Morgan Wealth Management LLC (0.39%) and Renaissance Technologies LLC (0.29%). Company insiders that own Isoray stock include Jonathan Robert Hunt, Lori A Woods, Mark John Austin, Michael Krachon, Philip J Vitale and William Cavanagh.
View institutional ownership trends for Isoray.

ISR stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC.
View insider buying and selling activity for Isoray or view top insider-selling stocks.

ISR stock was purchased by a variety of institutional investors in the last quarter, including Taylor & Morgan Wealth Management LLC, Bard Associates Inc., and State Street Corp. Company insiders that have bought Isoray stock in the last two years include Jonathan Robert Hunt, Lori A Woods, Mark John Austin, Michael Krachon, and Philip J Vitale.
View insider buying and selling activity for Isoray or or view top insider-buying stocks.

Shares of ISR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ISR stock can currently be purchased for approximately $0.28.

Isoray (NYSEAMERICAN:ISR) has a market capitalization of $39.49 million and generates $10.05 million in revenue each year. The healthcare company earns $-3.39 million in net income (profit) each year or ($0.05) on an earnings per share basis.

Isoray employs 61 workers across the globe.

Isoray's mailing address is 350 Hills St Ste 106, RICHLAND, WA 99354-5511, United States. The official website for Isoray is isoray.com. The healthcare company can be reached via phone at (509) 375-1202, via email at [email protected], or via fax at 509-267-3670.